Matches in SemOpenAlex for { <https://semopenalex.org/work/W2086728261> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2086728261 endingPage "376" @default.
- W2086728261 startingPage "372" @default.
- W2086728261 abstract "Purpose: Successful management of glaucoma and ocular hypertension requires patient compliance with the therapeutic regimen. Because ocular discomfort affects compliance, we compared the comfort of brimonidine 0.2%/timolol 0.5% and dorzolamide 2%/timolol 0.5%. Methods: In this single-centre, randomized, double-masked, internally controlled/paired-eye study, 30 subjects without a significant ocular surface disease received brimonidine 0.2%/timolol 0.5% in 1 eye and dorzolamide 2%/timolol 0.5% in the fellow eye. They evaluated discomfort at 30–40 s and 5 min postinstillation. Results: At 30–40 s, brimonidine 0.2%/timolol 0.5% provided significantly lower mean ocular discomfort scores than dorzolamide 2%/timolol 0.5% (P < 0.0001). This pattern persisted at 5 min but was not statistically significant. Significant differences were seen in the subjects' determination of the more comfortable treatment (P < 0.0001): brimonidine 0.2%/timolol 0.5% was rated as more comfortable than dorzolamide 2%/timolol 0.5% by 80% of subjects at 30–40 s and by 27% at 5 min. Only 10% of subjects at each time point rated dorzolamide 2%/timolol 0.5% as more comfortable. The remaining subjects reported no preference at either time point. No adverse events were reported. Conclusions: Brimonidine 0.2%/timolol 0.5% was significantly more comfortable than dorzolamide 2%/timolol 0.5% upon instillation. Patients with ocular hypertension or glaucoma may be more compliant with brimonidine 0.2%/timolol 0.5% treatment." @default.
- W2086728261 created "2016-06-24" @default.
- W2086728261 creator A5021135646 @default.
- W2086728261 creator A5039478629 @default.
- W2086728261 creator A5082200931 @default.
- W2086728261 date "2007-08-01" @default.
- W2086728261 modified "2023-10-17" @default.
- W2086728261 title "Ocular Comfort of Combination Glaucoma Therapies: Brimonidine 0.2%/Timolol 0.5% Compared with Dorzolamide 2%/Timolol 0.5%" @default.
- W2086728261 cites W1573690431 @default.
- W2086728261 cites W1636670833 @default.
- W2086728261 cites W1910727610 @default.
- W2086728261 cites W1963493193 @default.
- W2086728261 cites W1981201333 @default.
- W2086728261 cites W2014624081 @default.
- W2086728261 cites W2041031004 @default.
- W2086728261 cites W2070099990 @default.
- W2086728261 cites W2091063199 @default.
- W2086728261 cites W2110897487 @default.
- W2086728261 cites W2140594570 @default.
- W2086728261 cites W2148890166 @default.
- W2086728261 cites W4242144194 @default.
- W2086728261 doi "https://doi.org/10.1089/jop.2006.0131" @default.
- W2086728261 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17803436" @default.
- W2086728261 hasPublicationYear "2007" @default.
- W2086728261 type Work @default.
- W2086728261 sameAs 2086728261 @default.
- W2086728261 citedByCount "16" @default.
- W2086728261 countsByYear W20867282612014 @default.
- W2086728261 countsByYear W20867282612015 @default.
- W2086728261 countsByYear W20867282612021 @default.
- W2086728261 countsByYear W20867282612023 @default.
- W2086728261 crossrefType "journal-article" @default.
- W2086728261 hasAuthorship W2086728261A5021135646 @default.
- W2086728261 hasAuthorship W2086728261A5039478629 @default.
- W2086728261 hasAuthorship W2086728261A5082200931 @default.
- W2086728261 hasConcept C118487528 @default.
- W2086728261 hasConcept C2776521421 @default.
- W2086728261 hasConcept C2776727336 @default.
- W2086728261 hasConcept C2778073030 @default.
- W2086728261 hasConcept C2778190193 @default.
- W2086728261 hasConcept C2778527774 @default.
- W2086728261 hasConcept C2781092963 @default.
- W2086728261 hasConcept C42219234 @default.
- W2086728261 hasConcept C71924100 @default.
- W2086728261 hasConceptScore W2086728261C118487528 @default.
- W2086728261 hasConceptScore W2086728261C2776521421 @default.
- W2086728261 hasConceptScore W2086728261C2776727336 @default.
- W2086728261 hasConceptScore W2086728261C2778073030 @default.
- W2086728261 hasConceptScore W2086728261C2778190193 @default.
- W2086728261 hasConceptScore W2086728261C2778527774 @default.
- W2086728261 hasConceptScore W2086728261C2781092963 @default.
- W2086728261 hasConceptScore W2086728261C42219234 @default.
- W2086728261 hasConceptScore W2086728261C71924100 @default.
- W2086728261 hasIssue "4" @default.
- W2086728261 hasLocation W20867282611 @default.
- W2086728261 hasLocation W20867282612 @default.
- W2086728261 hasOpenAccess W2086728261 @default.
- W2086728261 hasPrimaryLocation W20867282611 @default.
- W2086728261 hasRelatedWork W1970476186 @default.
- W2086728261 hasRelatedWork W1979215550 @default.
- W2086728261 hasRelatedWork W2010755453 @default.
- W2086728261 hasRelatedWork W2014785256 @default.
- W2086728261 hasRelatedWork W2027345384 @default.
- W2086728261 hasRelatedWork W2128476364 @default.
- W2086728261 hasRelatedWork W2137843852 @default.
- W2086728261 hasRelatedWork W2612340917 @default.
- W2086728261 hasRelatedWork W3138731514 @default.
- W2086728261 hasRelatedWork W4245793165 @default.
- W2086728261 hasVolume "23" @default.
- W2086728261 isParatext "false" @default.
- W2086728261 isRetracted "false" @default.
- W2086728261 magId "2086728261" @default.
- W2086728261 workType "article" @default.